NovoCure (MEX:NVCRN) Cyclically Adjusted Book per Share: MXN69.80 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVCRN NovoCure Ltd MEX:NVCRN
70 GF Score
Price MXN322.39
GF Value MXN338.44
! 7 Warning Signs
View Full Analysis

What is NovoCure Cyclically Adjusted Book per Share?

NovoCure MEX:NVCRN 70 Cyclically Adjusted Book per Share is MXN69.80 as of Jun. 2026. GuruFocus rates MEX:NVCRN with a GF Score™ of 70/100 and a GF Value™ of MXN338.44. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

NovoCure's adjusted book value per share for the three months ended in Jun. 2026 was MXN50.664. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN69.80 for the trailing ten years ended in Jun. 2026.

During the past 12 months, NovoCure's average Cyclically Adjusted Book Growth Rate was 2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-14), NovoCure's current stock price is MXN322.39. NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was MXN69.80. NovoCure's Cyclically Adjusted PB Ratio of today is 4.62.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of NovoCure was 10.92. The lowest was 3.16. And the median was 5.27.


NovoCure  (MEX:NVCRN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NovoCure's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=322.39/69.80
=4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of NovoCure was 10.92. The lowest was 3.16. And the median was 5.27.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


NovoCure Cyclically Adjusted Book per Share Related Terms


NovoCure Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for NovoCure's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Cyclically Adjusted Book per Share Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 28.65 68.37

NovoCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.35 69.06 68.37 82.11 69.80

MEX:NVCRN vs NEOG, AXGN, UFPT: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted PB Ratio falls into.


MEX:NVCRN
70GF Score
NovoCure Ltd MEX:NVCRN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NovoCure's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=50.664/333.9520*333.9520
=50.664

Current CPI (Jun. 2026) = 333.9520.

NovoCure Quarterly Data

Book Value per Share CPI Adj_Book
201609 35.671 241.428 49.341
201612 33.707 241.432 46.624
201703 27.539 243.801 37.722
201706 23.973 244.955 32.683
201709 23.698 246.819 32.064
201712 24.926 246.524 33.766
201803 21.327 249.554 28.540
201806 23.808 251.989 31.552
201809 23.115 252.439 30.579
201812 23.637 251.233 31.420
201903 25.621 254.202 33.659
201906 31.192 256.143 40.667
201909 37.981 256.759 49.400
201912 41.270 256.974 53.633
202003 56.527 258.115 73.135
202006 61.194 257.797 79.271
202009 66.675 260.280 85.547
202012 92.629 260.474 118.759
202103 73.719 264.877 92.944
202106 76.302 271.696 93.786
202109 81.830 274.310 99.622
202112 80.993 278.802 97.014
202203 83.004 287.504 96.414
202206 84.844 296.311 95.622
202209 85.372 296.808 96.056
202212 81.877 296.797 92.127
202303 73.356 301.836 81.161
202306 66.849 305.109 73.168
202309 64.244 307.789 69.705
202312 57.465 306.746 62.562
202403 55.425 312.332 59.262
202406 61.356 314.175 65.218
202409 65.716 315.301 69.603
202412 69.222 315.605 73.246
202503 66.423 319.799 69.363
202506 58.853 322.561 60.931
202509 55.916 324.800 57.492
202512 54.495 324.054 56.160
202603 51.491 330.213 52.074
202606 50.664 333.952 50.664

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN69.80 mean?
NovoCure (MEX:NVCRN) has a Cyclically Adjusted Book per Share of MXN69.80 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on NovoCure and its competitors.
Is NovoCure's Cyclically Adjusted Book per Share too high?
NovoCure's current Cyclically Adjusted Book per Share is MXN69.80. Overall, NovoCure has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Cyclically Adjusted Book per Share compare to NEOG and AXGN?
NovoCure's Cyclically Adjusted Book per Share of MXN69.80 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on NovoCure and its competitors. NovoCure's current Cyclically Adjusted Book per Share is MXN69.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
NovoCure (MEX:NVCRN) has a current Cyclically Adjusted Book per Share of MXN69.80. The stock's GF Value™ is MXN338.44, compared to a current price of MXN322.39 — trading 4.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN69.80. NovoCure's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For NovoCure (MEX:NVCRN), the current Cyclically Adjusted Book per Share is MXN69.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (MEX:NVCRN) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of MXN322.39 is trading 4.7% below its estimated GF Value™ of MXN338.44.

Key valuation signals for MEX:NVCRN:

  • Cyclically Adjusted Book per Share: MXN69.80
  • GF Value™: MXN338.44 vs. price of MXN322.39 (4.7% below fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVCRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score

Get the complete analysis for MEX:NVCRN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN322.39
Price
MXN338.44
GF Value